The U.S. Food and Drug Administration (FDA) has yet to approve several popular nicotine pouch products for sale, despite introducing a fast-track review program aimed at accelerating decisions. According to sources familiar with the process, agency scientists remain cautious due to potential risks, particularly the possibility of increased nicotine addiction among non-users, including children and young adults. While nicotine pouches—placed under the lip for a stimulant effect—are considered less harmful than traditional cigarettes, regulators are carefully weighing their public health impact before granting authorization.
The delay poses a challenge for major tobacco companies such as Philip Morris International and British American Tobacco, which have pending applications for their leading brands, Zyn and Velo. Although the FDA approved six nicotine pouch products under Altria’s on! brand in December, other applications remain under review due to inconclusive scientific evidence. The agency is assessing whether these products can effectively help smokers transition away from more harmful tobacco use without encouraging new users to develop nicotine dependence.
Regulatory scrutiny has intensified as nicotine pouch usage rises across the United States, particularly among younger demographics. While overall usage among middle and high school students remains relatively low, recent data indicates a gradual increase. Public health advocates warn that aggressive marketing and growing popularity could fuel future addiction trends. The FDA maintains that its decisions will continue to be guided by scientific evidence and legal standards, even as it faces mounting pressure from industry stakeholders and policymakers to expand product approvals.
Pic Courtesy: google/ images are subject to copyright
